Hikma Pharmaceuticals Plc Hikma enters licensing partnership with Perrigo
09 July 2018 - 6:00PM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
09 July 2018
London, 9 July 2018 - Hikma Pharmaceuticals PLC (Hikma, Group)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's /
BB+ S&P, both stable) announces that it has signed a licensing
and distribution agreement with Omega Pharma Trading NV, an
affiliate of Perrigo Company plc (Perrigo), one of the largest
providers of over-the-counter healthcare solutions in Europe.
Under the terms of the agreement, Hikma has the exclusive right
to license and distribute more than 30 consumer healthcare
products, including Davitamon, Prevalin, XLS Medical, Dermalex and
Paranix, in all its MENA markets, with the exception of current
agreements in place. Hikma aims to work with Perrigo's existing
partners in the MENA region to broaden sales and marketing
coverage.
In addition, Hikma has the right of first refusal to the full
range of Perrigo's OTC medicines in the region.
The partnership provides a significant opportunity for Hikma to
collaborate with Perrigo in MENA, building on the strengths of each
company. The agreement will leverage Hikma's substantial local
presence with operations in 17 markets and an established sales and
marketing team, experienced in building brands, with particular
expertise in the consumer health business.
Mazen Darwazah, Executive Vice Chairman, Chief Executive of MENA
and Emerging Markets said, "We are very pleased to be entering a
partnership with Perrigo. This agreement will expand our consumer
healthcare portfolio, enabling us to meet growing demand across the
region."
Svend Andersen, Perrigo Executive Vice President and President,
Consumer Healthcare International, stated, "These OTC medicines are
important in meeting the healthcare needs of patients and
consumers. We are pleased to partner with Hikma to leverage their
strong presence in MENA markets, further increasing access to these
valuable consumer products.
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal
VP Corporate Strategy and Director +44 (0)20 7399 2760/ +44 7776
of Investor Relations 477050
Virginia Spring +44 (0)20 3892 4389/ +44 7973
Investor Relations Manager 679502
FTI Consulting
Ben Atwell/Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma helps put better health within reach every day for
millions of people in more than 50 countries around the world. For
40 years, we've been creating high-quality medicines and making
them accessible to the people who need them. We're a global company
with a local presence across the United States (US), the Middle
East and North Africa (MENA) and Europe, and we use our unique
insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed
to our customers, and the people they care for, and by thinking
creatively and acting practically, we provide them with a broad
range of branded and non-branded generic medicines. Together, our
8,500 colleagues are helping to shape a healthier world that
enriches all our communities. We are a leading licensing partner in
the MENA region, and through our venture capital arm, are helping
bring innovative health technologies to people around the world.
For more information, please visit www.hikma.com.
Perrigo Company PLC
Perrigo Company plc, a leading global healthcare company,
delivers value to its customers and consumers by providing Quality
Affordable Healthcare Products(R) . Founded in 1887 as a packager
of home remedies, Perrigo has built a unique business model that is
best described as the convergence of a fast-moving consumer goods
company, a high-quality pharmaceutical manufacturing organization
and a world-class supply chain network. Perrigo is one of the
world's largest manufacturers of OTC healthcare products and
suppliers of infant formulas for the store brand market. The
Company also is a leading provider of branded OTC products
throughout Europe and the U.S., as well as a leading producer of
"extended topical" prescription drugs. Perrigo, headquartered in
Ireland, sells its products primarily in North America and Europe,
as well as in other markets, including Australia, Israel and China.
Visit Perrigo online http://www.perrigo.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAMMGGNVKKGRZM
(END) Dow Jones Newswires
July 09, 2018 04:00 ET (08:00 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024